Subareolar versus peritumoral injection for location of the sentinel lymph node

Vicki Klimberg, Isabel T. Rubio, Ronda Henry, Christopher Cowan, Maureen Colvert, Soheila Korourian

Research output: Contribution to journalArticle

299 Citations (Scopus)

Abstract

Background: Sentinel lymph node (SLN) biopsy is fast becoming the standard for testing lymph node involvement in many institutions. However, questions remain as to the best method of injection. The authors hypothesized that a subareolar injection of material would drain to the same lymph node as a peritumoral injection, regardless of the location of the tumor. Methods: To test this theory, 68 patients with 69 operable invasive breast carcinomas and clinically node-negative disease were enrolled in this single-institution Institutional Review Board-approved trial. Patients were injected with 1.0 mCi of technetium-99 sulfur colloid (unfiltered) in the subareolar area of the tumor-bearing breast. Each patient received an injection of 2 to 5 cc of isosulfan blue around the tumor. Radioactive SLNs were identified using a hand-held gamma detector probe. Results: The average age of patients entered into this trial was 55.2 ± 13.4 years. The average size of the tumors was 1.48 ± 1.0 cm. Thirty-two percent of the patients had undergone previous excisional breast biopsies. Of the 69 lesions, 62 (89.9%) had SLNs located with the blue dye and 65 (94.2%)with the technetium. In four patients, the SLN was not located with either method. All blue SLNs were also radioactive. All located SLNs were in the axilla. Of the 62 patients in which the SLNs were located with both methods, an average of 1.5 ± 0.7 SLNs were found per patient, of which 23.2% had metastatic disease. All four patients in which no SLN was located with either method had undergone prior excisional biopsies. Conclusions: The results of this study suggest that subareolar injection of technetium is as accurate as peritumoral injection of blue dye. Central injection is easy and avoids the necessity for image-guided injection of nonpalpable breast lesions. Finally, subareolar injection of technetium avoids the problem of overlap of the radioactive zone of diffusion of the injection site with the radioactive sentinel lymph node, particularly in medial and upper outer quadrant lesions.

Original languageEnglish (US)
Pages (from-to)860-865
Number of pages6
JournalAnnals of Surgery
Volume229
Issue number6
DOIs
StatePublished - Jun 1999
Externally publishedYes

Fingerprint

Injections
Technetium
Breast
Coloring Agents
Lymph Nodes
Technetium Tc 99m Sulfur Colloid
Sentinel Lymph Node
Breast Neoplasms
Biopsy
Sentinel Lymph Node Biopsy
Neoplasms
Axilla
Research Ethics Committees
Hand

ASJC Scopus subject areas

  • Surgery

Cite this

Subareolar versus peritumoral injection for location of the sentinel lymph node. / Klimberg, Vicki; Rubio, Isabel T.; Henry, Ronda; Cowan, Christopher; Colvert, Maureen; Korourian, Soheila.

In: Annals of Surgery, Vol. 229, No. 6, 06.1999, p. 860-865.

Research output: Contribution to journalArticle

Klimberg, Vicki ; Rubio, Isabel T. ; Henry, Ronda ; Cowan, Christopher ; Colvert, Maureen ; Korourian, Soheila. / Subareolar versus peritumoral injection for location of the sentinel lymph node. In: Annals of Surgery. 1999 ; Vol. 229, No. 6. pp. 860-865.
@article{4027f784cded43ae9ece4991ef775704,
title = "Subareolar versus peritumoral injection for location of the sentinel lymph node",
abstract = "Background: Sentinel lymph node (SLN) biopsy is fast becoming the standard for testing lymph node involvement in many institutions. However, questions remain as to the best method of injection. The authors hypothesized that a subareolar injection of material would drain to the same lymph node as a peritumoral injection, regardless of the location of the tumor. Methods: To test this theory, 68 patients with 69 operable invasive breast carcinomas and clinically node-negative disease were enrolled in this single-institution Institutional Review Board-approved trial. Patients were injected with 1.0 mCi of technetium-99 sulfur colloid (unfiltered) in the subareolar area of the tumor-bearing breast. Each patient received an injection of 2 to 5 cc of isosulfan blue around the tumor. Radioactive SLNs were identified using a hand-held gamma detector probe. Results: The average age of patients entered into this trial was 55.2 ± 13.4 years. The average size of the tumors was 1.48 ± 1.0 cm. Thirty-two percent of the patients had undergone previous excisional breast biopsies. Of the 69 lesions, 62 (89.9{\%}) had SLNs located with the blue dye and 65 (94.2{\%})with the technetium. In four patients, the SLN was not located with either method. All blue SLNs were also radioactive. All located SLNs were in the axilla. Of the 62 patients in which the SLNs were located with both methods, an average of 1.5 ± 0.7 SLNs were found per patient, of which 23.2{\%} had metastatic disease. All four patients in which no SLN was located with either method had undergone prior excisional biopsies. Conclusions: The results of this study suggest that subareolar injection of technetium is as accurate as peritumoral injection of blue dye. Central injection is easy and avoids the necessity for image-guided injection of nonpalpable breast lesions. Finally, subareolar injection of technetium avoids the problem of overlap of the radioactive zone of diffusion of the injection site with the radioactive sentinel lymph node, particularly in medial and upper outer quadrant lesions.",
author = "Vicki Klimberg and Rubio, {Isabel T.} and Ronda Henry and Christopher Cowan and Maureen Colvert and Soheila Korourian",
year = "1999",
month = "6",
doi = "10.1097/00000658-199906000-00013",
language = "English (US)",
volume = "229",
pages = "860--865",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Subareolar versus peritumoral injection for location of the sentinel lymph node

AU - Klimberg, Vicki

AU - Rubio, Isabel T.

AU - Henry, Ronda

AU - Cowan, Christopher

AU - Colvert, Maureen

AU - Korourian, Soheila

PY - 1999/6

Y1 - 1999/6

N2 - Background: Sentinel lymph node (SLN) biopsy is fast becoming the standard for testing lymph node involvement in many institutions. However, questions remain as to the best method of injection. The authors hypothesized that a subareolar injection of material would drain to the same lymph node as a peritumoral injection, regardless of the location of the tumor. Methods: To test this theory, 68 patients with 69 operable invasive breast carcinomas and clinically node-negative disease were enrolled in this single-institution Institutional Review Board-approved trial. Patients were injected with 1.0 mCi of technetium-99 sulfur colloid (unfiltered) in the subareolar area of the tumor-bearing breast. Each patient received an injection of 2 to 5 cc of isosulfan blue around the tumor. Radioactive SLNs were identified using a hand-held gamma detector probe. Results: The average age of patients entered into this trial was 55.2 ± 13.4 years. The average size of the tumors was 1.48 ± 1.0 cm. Thirty-two percent of the patients had undergone previous excisional breast biopsies. Of the 69 lesions, 62 (89.9%) had SLNs located with the blue dye and 65 (94.2%)with the technetium. In four patients, the SLN was not located with either method. All blue SLNs were also radioactive. All located SLNs were in the axilla. Of the 62 patients in which the SLNs were located with both methods, an average of 1.5 ± 0.7 SLNs were found per patient, of which 23.2% had metastatic disease. All four patients in which no SLN was located with either method had undergone prior excisional biopsies. Conclusions: The results of this study suggest that subareolar injection of technetium is as accurate as peritumoral injection of blue dye. Central injection is easy and avoids the necessity for image-guided injection of nonpalpable breast lesions. Finally, subareolar injection of technetium avoids the problem of overlap of the radioactive zone of diffusion of the injection site with the radioactive sentinel lymph node, particularly in medial and upper outer quadrant lesions.

AB - Background: Sentinel lymph node (SLN) biopsy is fast becoming the standard for testing lymph node involvement in many institutions. However, questions remain as to the best method of injection. The authors hypothesized that a subareolar injection of material would drain to the same lymph node as a peritumoral injection, regardless of the location of the tumor. Methods: To test this theory, 68 patients with 69 operable invasive breast carcinomas and clinically node-negative disease were enrolled in this single-institution Institutional Review Board-approved trial. Patients were injected with 1.0 mCi of technetium-99 sulfur colloid (unfiltered) in the subareolar area of the tumor-bearing breast. Each patient received an injection of 2 to 5 cc of isosulfan blue around the tumor. Radioactive SLNs were identified using a hand-held gamma detector probe. Results: The average age of patients entered into this trial was 55.2 ± 13.4 years. The average size of the tumors was 1.48 ± 1.0 cm. Thirty-two percent of the patients had undergone previous excisional breast biopsies. Of the 69 lesions, 62 (89.9%) had SLNs located with the blue dye and 65 (94.2%)with the technetium. In four patients, the SLN was not located with either method. All blue SLNs were also radioactive. All located SLNs were in the axilla. Of the 62 patients in which the SLNs were located with both methods, an average of 1.5 ± 0.7 SLNs were found per patient, of which 23.2% had metastatic disease. All four patients in which no SLN was located with either method had undergone prior excisional biopsies. Conclusions: The results of this study suggest that subareolar injection of technetium is as accurate as peritumoral injection of blue dye. Central injection is easy and avoids the necessity for image-guided injection of nonpalpable breast lesions. Finally, subareolar injection of technetium avoids the problem of overlap of the radioactive zone of diffusion of the injection site with the radioactive sentinel lymph node, particularly in medial and upper outer quadrant lesions.

UR - http://www.scopus.com/inward/record.url?scp=0033510722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033510722&partnerID=8YFLogxK

U2 - 10.1097/00000658-199906000-00013

DO - 10.1097/00000658-199906000-00013

M3 - Article

VL - 229

SP - 860

EP - 865

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -